Caris Life Sciences EPS History: Annual & Quarterly (CAI)
Caris Life Sciences's diluted EPS was -$3.22 for fiscal 2025.
View full Caris Life Sciences company overviewCaris Life Sciences annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$3.22 | -$3.22 | $7.44 | — |
| 2024 | 2024-12-31 | -$10.66 | -$10.66 | $2.58 | — |
| 2023 | 2023-12-31 | -$13.24 | -$13.24 | -$11.67 | — |
| 2022 | 2022-12-31 | -$1.57 | -$1.57 | — | — |
Caris Life Sciences quarterly diluted eps
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.00 | $0.00 | $7.97 | — |
| Q1 2026 | 2026-03-31 | $0.00 | $0.00 | $3.57 | — |
| Q4 2025 | 2025-12-31 | $0.28 | $0.29 | — | — |
| Q3 2025 | 2025-09-30 | $0.08 | $0.09 | $2.67 | — |
| Q2 2025 | 2025-06-30 | -$7.97 | -$7.97 | -$5.43 | — |
| Q1 2025 | 2025-03-31 | -$3.57 | -$3.57 | — | — |
| Q3 2024 | 2024-09-30 | -$2.59 | -$2.59 | — | — |
| Q2 2024 | 2024-06-30 | -$2.54 | -$2.54 | — | — |
Caris Life Sciences diluted eps trends
Between the periods ended 2022-12-31 and 2025-12-31, Caris Life Sciences's diluted eps decreased from -$1.57 to -$3.22, a change of -$1.65. The latest reported quarter, Q2 2026, shows $0.00.
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Caris Life Sciences source filings ↗